

## Contents

### Volume 1

**Preface** V

**List of Contributors** XXXIX

### Part A **Dendritic Cell Biology** 1

#### **1 Introduction to Some of the Issues and Mysteries Considered in this Book on Dendritic Cells** 3

*Ralph M. Steinman*

- 1.1 Dendritic Cells as a Distinct Hematopoietic Lineage 3
  - 1.1.1 Chapters 1–16, the Life History of Dendritic Cells 3
  - 1.1.2 Questions Concerning the Dendritic Cell Lineage 4
- 1.2 Control of Lymphocyte Responses by Dendritic Cells 4
  - 1.2.1 Chapters 17–30, Initiation of Immunity 4
  - 1.2.2 Questions Concerning Antigen Uptake, Processing and Presentation 5
  - 1.2.3 Questions Concerning Dendritic Cell Maturation 5
- 1.3 Dendritic Cells in Disease Pathogenesis 6
  - 1.3.1 Chapters 31–51, Dendritic Cells in Infectious and Other Diseases 6
  - 1.3.2 Some Questions on the Roles of Dendritic Cells in Diseases 7
- 1.4 Dendritic Cells and the Design of Vaccines and New Therapies 7
  - 1.4.1 Chapters 52–55, Dendritic Cells in Immunotherapy 7
  - 1.4.2 Dendritic Cells and the Design of Vaccines against Infectious Diseases 8
  - References 9

#### **I Dendritic Cell Development** 13

#### **2 Bone Marrow Progenitors of Dendritic and Natural Interferon-producing Cells** 13

*Markus G. Manz*

- 2.1 Hematopoietic Stem Cells and Successive Lineage-restricted Early Hematopoietic Progenitor Cells 14

2.2	Proposed Models for Dendritic and Natural Interferon-producing Cell Differentiation	15
2.3	Unexpected Redundancy in Dendritic and Natural Interferon-producing Cell Development from both Lymphoid and Myeloid Restricted Hematopoietic Progenitor Cells	16
2.4	Immediate Dendritic and Natural Interferon-producing Cell Precursors	17
2.5	Proposed “flt3-license” Working Model for Steady-State Dendritic and Natural Interferon-producing Cell Development from Early Hematopoietic Progenitor Cells	18
2.6	Conclusions	20
	Acknowledgement	21
	References	21
<b>3</b>	<b>Growth Factors</b>	<b>27</b>
	<i>Herbert Strobl, Barbara Platzner, Almut Jörgl, Sabine Taschner, Leonhard Heinz and Peter Reisner</i>	
3.1	Introduction	27
3.2	Short Description of Key Cytokines Involved in DC Development	28
3.2.1	Flt3 Ligand (FLT3L, FL)	28
3.2.2	GM-CSF (Granulocyte-macrophage Colony-stimulating Factor)	29
3.2.3	Interleukin 3 (IL-3)	30
3.2.4	Interleukin 4 (IL-4)	30
3.2.5	Interleukin-15 (IL-15)	31
3.2.6	TNF $\alpha$ (Tumor Necrosis Factor-alpha)	31
3.2.7	TGF- $\beta$ 1 (Transforming Growth Factor Beta-1)	32
3.3	Regulation of <i>in vitro</i> DC Hematopoiesis by Cooperating Cytokine Signals	33
3.3.1	Cytokines in the Induction and Amplification of CD1a <sup>+</sup> Myeloid DC Subsets from Hematopoietic Progenitor Cells <i>in vitro</i>	33
3.3.2	Cytokines for Pre-expansion of Myeloid DC Progenitor Cells	35
3.3.3	Cytokine Combinations that Promote Myeloid DC Expansion Reciprocally Inhibit Plasmacytoid DC Development in Suspension Cultures	36
3.3.4	TGF- $\beta$ 1 and its Essential Co-signals for LC Differentiation from Hematopoietic Progenitor/Stem Cells	39
3.3.5	TGF- $\beta$ 1 Induces LC Differentiation from Monocyte Intermediates	40
3.3.6	Redundancy among Cytokine Signals Directing LC Differentiation from CD34 <sup>+</sup> Hematopoietic Progenitor Cells	41
3.3.7	TGF- $\beta$ 1-dependent LC Induction by <i>in vivo</i> Occurring Candidate Precursors	41
3.3.8	Cytokines Promoting the Generation of Monocyte-derived DC	42
3.3.9	Evidence for Cellular Heterogeneity of DC Arising from CD34 <sup>+</sup> Progenitors or Monocytes	43
3.4	Conclusions	43
	References	44

<b>4</b>	<b>Transcription Factors: Deciphering the Transcription Factor Network of Dendritic Cell Development</b>	<b>53</b>
	<i>Thomas Hieronymus and Martin Zenke</i>	
4.1	Introduction	53
4.2	Ikaros	54
4.3	RelB	55
4.4	PU.1	56
4.5	C/EBPa	57
4.6	Pax5	60
4.7	IRF family	60
4.8	Id2	63
4.9	Runx3	64
4.10	Gfi1	64
4.11	Concluding Remarks	65
	References	66
<b>II</b>	<b>Sentinel Dendritic Cells in Nonlymphoid Organs</b>	<b>73</b>
<b>5</b>	<b>Epidermal Langerhans Cells</b>	<b>73</b>
	<i>Nikolaus Romani, Christoph H. Tripp, Gudrun Ratzinger, Christine Heufler, Franz Koch, Sem Saeland and Patrizia Stoitzner</i>	
5.1	Introduction and Definition	73
5.2	A Short Review of the History of Langerhans Cells	73
5.3	Characterization and Morphology of Langerhans Cells	75
5.4	Entry of Langerhans Cells into the Epidermis in Ontogeny and Adulthood	76
5.4.1	Entry of Langerhans Cells into the Epidermis during Ontogeny	76
5.4.2	Entry and Turnover of Langerhans Cells into the Adult Epidermis under Homeostatic Conditions	77
5.4.3	Entry and Turnover of Langerhans Cells into the Adult Epidermis under Inflammatory Conditions	78
5.5	Lineage of Langerhans Cells	79
5.6	Langerhans Cells in Lymphoid Organs	80
5.7	Langerhans Cells as a Paradigm for Dendritic Cell Function	82
5.8	The Changing of the Paradigm	84
5.9	Can Langerhans Cells Induce Immunity <i>in vivo</i> ?	85
5.10	Can Langerhans Cells maintain Peripheral Tolerance <i>in vivo</i> ?	86
5.11	Can Langerhans Cells be Applied in Immunotherapy?	88
5.12	Recent Methodical Advances Relevant for the Study of Langerhans Cells	89
	Acknowledgements	90
	References	90

<b>6</b>	<b>Characterization of Dendritic Cells and other Antigen-presenting Cells in the Eye</b>	<b>101</b>
	<i>Joan Stein-Streilein</i>	
6.1	Introduction	101
6.2	APC in Various Regions of the Eye	103
6.3	DC/APC in the Retina	103
6.4	DC/APC in the Cornea	105
6.5	DC/APC in the Anterior Chamber	105
6.6	Mechanisms of ACAID Induction in the Spleen	107
6.7	The Role of the F4/80 Protein in ACAID	109
6.8	Therapeutic Potential of ACAID APC	110
6.9	Conclusions and Implications	111
	Acknowledgements	111
	Abbreviations	112
	References	112
<b>7</b>	<b>Toll-like Receptors</b>	<b>119</b>
	<i>Hubertus Hochrein and Hermann Wagner</i>	
7.1	TLR and their Ligands	119
7.2	TLR Subfamilies	121
7.3	TLR and Dendritic Cell Subsets	122
7.4	TLR Signaling	123
7.5	What Determines the Outcome of the Immune Responses?	124
	References	126
<b>8</b>	<b>C-type Lectins on Dendritic Cells: Antigen Receptors and Modulators of Immune Responses</b>	<b>129</b>
	<i>Yvette van Kooyk and Teunis B.H. Geijtenbeek</i>	
8.1	Introduction	129
8.2	DCs and Antigen Recognition Receptors	130
8.3	CLRs as Antigen Receptors for Homeostatic Control	130
8.4	CLRs as Adhesion Receptors	131
8.5	CLRs as Pathogen Receptors	133
8.5.1	HIV-1 as Prototypic Example for Virus-DC-SIGN Interactions	133
8.6	Glycan Modifications and Pathogen Recognition by DCs	134
8.7	CLRs as Signaling Receptors	136
8.8	CLRs and Recognition of Cancer	137
8.9	Concluding Remarks	137
	Abbreviations	138
	Acknowledgements	138
	References	139

- 9 Scavenger Receptors on Dendritic Cells 141**  
*Emma J. McKenzie, Subhankar Mukhopadhyay, Siamon Gordon and Luisa Martinez-Pomares*
- 9.1 Introduction 141
- 9.2 Structure and Binding Properties of Mammalian Scavenger Receptors 142
- 9.2.1 Class A Scavenger Receptors 143
- 9.2.1.1 SR-A I,II and III (SR-A) 143
- 9.2.1.2 MARCO 144
- 9.2.1.3 SRCL-I 146
- 9.2.2 CD36 147
- 9.2.3 LOX-1 148
- 9.2.4 SREC-I 149
- 9.2.5 Other Members of the SR Family 149
- 9.2.5.1 CD68 149
- 9.2.5.2 SR-B1, FEEL-1 and FEEL-2 150
- 9.3 Role of Scavenger Receptors in Dendritic Cell Biology 150
- 9.3.1 SR and Antigen Internalization for Presentation to the Acquired Immune System 151
- 9.3.1.1 *In vitro* Generation of SR Ligands and its Effect in Immunogenicity 151
- 9.3.1.2 Crosspresentation of Ag Through Uptake of Apoptotic Cells 152
- 9.3.1.3 Crosspresentation of Ag Acquired through Live Cell Nibbling 153
- 9.3.1.4 Crosspresentation of Peptide-chaperone Complexes 153
- 9.3.2 Role of SR in the Modulation of Dendritic Cell Activation 155
- 9.3.2.1 Role of SR in Modulation of Dendritic Cell Phenotype in Response to Uptake of Apoptotic Cells 155
- 9.3.2.2 Role of SR in Modulation of Dendritic Cell Phenotype in Response to Uptake of Necrotic Cells 155
- 9.3.2.3 Cross-talk between SR and Toll-like Receptors 156
- 9.4 Concluding Remarks 156
- References 157
- 10 Production of the Long Pentraxin PTX3 by Myeloid Dendritic Cells: Linking Cellular and Humoral Innate Immunity 165**  
*Paola Allavena, Barbara Bottazzi, Andrea Doni, Luigina Romani, Cecilia Garlanda and Alberto Mantovani*
- 10.1 Introduction 165
- 10.2 The Pentraxin Superfamily and the Prototypic Long PTX3: Molecules and Ligands 165
- 10.3 Myeloid DC as a Major Source of PTX3: Regulation of Production 168
- 10.4 Blood-circulating Myeloid, but not Plasmacytoid, DC Produce PTX3 169
- 10.5 Role of PTX3 in Innate Immunity 170

10.6 Function of Antigen Presenting Cells in PTX3-deficient Mice 170  
 10.7 Conclusion 171  
 References 172

**11 Gene Profiling of Dendritic cells during Host–Pathogen Interactions 175**

*Maria Foti, Francesca Granucci, Mattia Pelizzola, Norman Pavelka, Ottavio Beretta, Caterina Vizzardelli, Matteo Urbano, Ivan Zanoni, Giusy Capuano, Francesca Mingozzi, François Trottein, Toni Aebischer and Paola Ricciardi-Castagnoli*

11.1 Dendritic Cells as Sentinels of the Immune System: Tissue-resident DC and Migratory DC 175  
 11.2 Study of the Complexity of the Immune System using Gene Profiling 177  
 11.3 Discovery of IL2 Production by DC using Global Technologies and the NK-DC Interplay 179  
 11.4 Profiling of Pathogens and Cells of the Innate Response: Mucosal Epithelial Cells, Phagocytic Cells (Neutrophils and Macrophages) 180  
 11.5 Dendritic Cells and Pathogen Interaction: Dendritic Cells as a Link between Innate and Acquired Immunity 182  
 11.6 Dendritic Cells as Sensors of Infection 184  
 11.7 DC Transcriptional Profile Induced by Pathogen Teaches the Dynamic of the Interactions: DC Transcriptome; Core and Specific Responses 185  
 11.8 DC and *Shistosoma Mansonii* Specific Signature 186  
 11.9 DC and *Leishmania Mexicana*: Molecular Profile of the Interaction 190  
 11.10 Conclusions 192  
 References 192

**III Dendritic Cells in Secondary Lymphoid Organs 199**

**12 Dendritic Cell Subtypes 199**

*Ken Shortman and José A. Villadangos*

12.1 Introduction 199  
 12.2 DC Surface Antigen Heterogeneity and the Recognition of DC Subtypes 201  
 12.3 DC Subtypes in Steady-state versus Infected Mice 202  
 12.4 Extraction and Enrichment of DC from Lymphoid Tissue 203  
 12.5 Plasmacytoid versus Conventional DC 203  
 12.6 Spleen DC Subtypes 204  
 12.7 Lymph Node DC Subtypes 206  
 12.8 Thymic DC 208  
 12.9 The Maturation State of Lymphoid Organ DC Subtypes 209  
 12.10 Generation and Lifespan of DC Subtypes 210

- 12.11 Human DC Subtypes 211
- 12.12 Functional Differences between DC Subtypes 212  
References 212
- IV Circulating Dendritic Cells and their Precursors 219**
- 13 pDC: From Plasmacytoid Dendritic Cell Precursors to Professional Type 1 Interferon-producing Cells 219**  
*Yong-Jun Liu, Holger Kanzler, Yui-Hsi Wang, Yi-Hong Wang, Michel Gilliet, Wei Cao and Tomoki Ito*
- 13.1 Introduction 219
- 13.1.1 A Mysterious Cell Type with Plasmacytoid Morphology 219
- 13.1.2 A Mysterious Cell Type that has the Capacity to Produce Huge Amounts of Type 1 IFNs 221
- 13.1.3 From pDC to IPC 221
- 13.1.4 pDCs/IPCs in Mice, Rat, Pig, and Monkey 222
- 13.2 Isolation and Characterization of pDCs/IPCs 222
- 13.2.1 Isolation of Human pDCs/IPCs 222
- 13.2.2 Isolation of Mouse pDCs/IPCs 222
- 13.2.3 pDC/IPC Morphology 223
- 13.2.4 Surface Phenotype of pDCs/IPCs 224
- 13.3 pDC/IPC Development 224
- 13.4 Localization, Migration, and Lifespan of pDCs/IPCs 227
- 13.5 Innate Immune Response by pDCs/IPCs 228
- 13.5.1 pDCs/IPCs Selectively Express Intracellular TLR-7 and TLR-9 that Respectively Recognize Single-Stranded RNA and Double-Stranded DNA 228
- 13.5.2 pDCs/IPCs Are Professional Type 1 IFN-Producing Cells 229
- 13.5.3 pDCs/IPCs Rapidly Produce Large Amounts of IFN- $\alpha$  that Is Independent of Positive Feedback of IFN- $\beta$  Through Type 1 IFN Receptors 230
- 13.5.4 TLR7/TLR9-mediated IFN- $\alpha$  production by pDCs/IPCs depends on Myd88-IRAK4-TRAF6-IRF-7 complexes 231
- 13.5.5 Human pDCs/IPCs Have a Limited Ability to Produce IL-12 231
- 13.5.6 Myeloid DCs Are Specialized in Producing IL-12, but not Type 1 IFNs 233
- 13.6 Regulation of T-cell-mediated Immune Responses by pDCs/IPCs 233
- 13.6.1 pDC/IPC Differentiation to Mature DCs through Two Pathways 233
- 13.6.2 pDC-Derived DCs Induce Th1 by IFN- $\alpha$  but not IL-12 235
- 13.6.3 pDC-Derived DCs Induce Th2 through OX40L 235
- 13.6.4 pDC-Derived DCs and their Ability to Prime Naïve versus Memory T Cells 235
- 13.6.5 pDC-Derived DCs and Presentation of Endogenous and Exogenous Antigens 235
- 13.6.6 pDCs/IPCs and Cross-priming 236

13.6.7	pDCs/IPCs and Regulatory T Cells	236
13.7	pDCs/IPCs Regulate the Function of Conventional Myeloid DC by Type 1 IFN	237
13.8	Regulation of NK Cell Function by pDCs/IPCs	238
13.9	Regulation of B-cell Function by pDCs/IPCs	239
13.10	pDCs/IPCs and Human Diseases	239
13.10.1	HIV	239
13.10.2	Systemic Lupus Erythematosus (SLE)	239
13.10.3	Cancer	240
13.11	Conclusion	240
	Acknowledgments	241
	References	241
<b>14</b>	<b>Monocyte subsets and their relation to DCs</b>	<b>253</b>
	<i>Brigitte Senechal, Darin Fogg, Gaelle Elain, and Frederic Geissmann</i>	
14.1	Monocytes and the Concept of the “Mononuclear Phagocyte System” (MPS)	254
14.1.1	Blood Monocytes in the Mononuclear Phagocyte System	254
14.1.2	Plasticity of Monocytes as Studied <i>in vitro</i> and its Relevance to DC Differentiation <i>in vivo</i>	256
14.1.3	Contribution of Monocytes to Long-lived Resident Cells in Peripheral Tissues	257
14.1.4	Contribution of Monocytes to Short-lived Bone Marrow-derived Steady State Macrophages and DC	258
14.1.5	Evidence that Monocytes Contribute to Short-lived Migrating Dendritic Cells that Differentiate During Inflammation and Infection	259
14.1.6	Summary of the Respective Contribution of Monocytes to Individual Subsets of the MPS System	260
14.2	Molecular Determinants of Monocyte Differentiation	260
14.3.2	Monocyte Subsets	262
14.3.3	CCR2 <sup>+</sup> CX3CR1 <sup>low</sup> “Inflammatory” Monocytes	264
14.3.4	The Enigmatic CCR2 <sup>-</sup> CX3CR1 <sup>high</sup> Monocytes	265
14.3.5	Relationship Between CCR2 <sup>+</sup> CX3CR1 <sup>low</sup> Monocytes and CCR2 <sup>-</sup> CX3CR1 <sup>high</sup> Monocytes	266
14.3.6	Additional Subsets of Monocytes?	266
14.4	Migration of Monocytes and Their Recruitment to Tissues	267
14.4.1	Monocyte Entry into the Target Tissues	267
14.4.2	Baseline Extravasation of Monocytes	268
14.4.3	Recruitment of Monocytes During Inflammation and Infection	268
14.5	Concluding remarks	269
	Acknowledgments	270
	References	270



<b>V</b>	<b>Dendritic Cell Migration</b>	<b>279</b>
<b>15</b>	<b>Steady State Migration of Dendritic Cells in Lymph</b>	<b>279</b>
	<i>Gordon MacPherson, Simon Milling, Emma Turnbull and Ulf Yrlid</i>	
15.1	Introduction	279
15.1.1	Dendritic Cells	279
15.1.2	Why Study Lymph Dendritic Cells?	280
15.1.3	Lymphatic Terminology	280
15.1.4	Historical	281
15.2	Dendritic Cells in the Periphery	281
15.2.1	Constitutive Migration of Dendritic Cells from Peripheral Tissues	281
15.2.2	Exit of Dendritic Cells from Peripheral Tissues	282
15.2.3	Entry of Dendritic Cells into Peripheral Lymph	282
15.3	Lymph Dendritic Cells	282
15.3.1	Pseudo-afferent Lymph	282
15.4	Properties of Lymph Dendritic Cells in the Rat	283
15.4.1	Steady-state Output	283
15.4.2	Origin of Afferent Lymph Dendritic Cells	283
15.4.3	Steady-state Rat Lymph Dendritic Cells are “Semi-mature”	284
15.4.4	Subsets of Rat Lymph Dendritic Cells	284
15.4.5	Migratory Fate of Lymph Dendritic Cells	285
15.4.6	Uptake and Transport of Apoptotic Cells by Intestinal Dendritic Cells	286
15.5	Dendritic Cells and B Cells	286
15.6	Dendritic Cells and the Pathogenesis of Transmissible Spongiform Encephalopathies (TSE)	287
15.7	Conclusions	288
	References	288
<b>16</b>	<b>Multiple Pathways to Control DC Migration</b>	<b>295</b>
	<i>Karel Otero, Elena Riboldi, Annalisa Del Prete, Annunciata Vecchi, Fabio Facchetti, Alberto Mantovani and Silvano Sozzani</i>	
16.1	Dendritic Cells as Professional Migratory Cells	295
16.2	Role of Chemokines in the Recruitment of Myeloid and Plasmacytoid Dendritic Cells	296
16.3	Migration of Mature Dendritic Cells to Secondary Lymphoid Organs	298
16.4	Chemotactic Factors for Dendritic Cells: more than Chemokines	301
16.5	Tuning Dendritic Cell Migration by Nonchemotactic Signals	303
16.6	Concluding Remarks	305
	Acknowledgements	305
	References	306

<b>VI</b>	<b>T-cell Activation and Co-stimulation</b>	<b>313</b>
<b>17</b>	<b>Antigen Processing and Presentation: CD1d and NKT cells</b>	<b>313</b>
	<i>Serani L.H. van Dommelen, Dale I. Godfrey and Mark J. Smyth</i>	
17.1	Introduction	313
17.2	CD1d and Antigen Presentation	313
17.2.1	The CD1d Molecule	313
17.2.2	Nature of CD1d and Glycolipid Recognition by TCR	315
17.2.3	Nature of CD1d-expressing APC	316
17.3	CD1d-restricted NKT Cells	318
17.3.1	Defining NKT Cells	318
17.3.2	Tissue Location and NKT Cell Subsets	319
17.4	Nature of the Antigens Presented by CD1d-expressing APC to NKT Cells	319
17.4.1	Self-ligands	320
17.4.2	Naturally-occurring Exogenous Ligands	320
17.4.3	Synthetic Ligands	321
17.5	Effector Functions of NKT Cells	321
17.5.1	Cytokine Secretion and Cytotoxicity of NKT Cells	322
17.5.2	The Initial Cross-talk Between CD1d-expressing APC and NKT Cells	322
17.5.3	Functional Diversity of NKT Cell Responses	323
17.5.4	Modulation of Downstream Immune Responses by a-GalCer-activated Cells	325
17.5.5	Adjuvant-like Effect of NKT Cells on DC Mediated Antigen Presentation	327
17.6	Role of CD1d-restricted NKT Cells in Disease Models	328
17.7	Conclusions	328
	Acknowledgments	328
	References	329
<b>18</b>	<b>The Role of Dendritic Cells in T-cell Activation and Differentiation</b>	<b>343</b>
	<i>Federica Sallusto and Antonio Lanzavecchia</i>	
18.1	Introduction	343
18.2	Requirements for Activation of Naïve T Lymphocytes	343
18.2.1	Co-stimulatory and Inhibitory Pathways	345
18.2.2	Differentiation to Effector T Cells	345
18.3	Dendritic Cell Maturation	346
18.4	T-cell Priming by Dendritic Cells	347
18.4.1	Priming of Th1 and Inflammatory T-cell Responses	348
18.4.2	Priming of Th2 Cells	348
18.4.3	Imprinting Tissue Homing Receptors	349
18.4.4	The Role of Plasmacytoid Dendritic Cells in T-cell Responses	349
18.5	Concluding Remarks	350
	References	350

**19 Cytokines Produced by Dendritic Cells 355***David F. Tough*

- 19.1 Introduction 355
- 19.2 DC Cytokine Expression: A Few Caveats 355
- 19.3 Type I Interferon 356
- 19.4 IL-12, IL-23, IL-27 357
- 19.5 IL-18 359
- 19.6 IL-6 360
- 19.7 IL-1 360
- 19.8 TNF- $\alpha$  362
- 19.9 Concluding Remarks 363
- Acknowledgement 364
- References 364

**Volume 2****VII Th1 and Th2 Decision 385****20 The Plasticity of Dendritic Cells Populations in Promoting Th-cell Responses 385***André Boonstra, Giorgio Trinchieri and Anne O'Garra*

- 20.1 Effector Th-cell Populations 385
- 20.2 Factors Inducing the Development of Th1 or Th2 Cells 386
- 20.2.1 The Strength of DC–Th-cell Interaction 387
- 20.2.2 Co-stimulators 388
- 20.2.3 Genetic Background 388
- 20.3 Opposing Concepts: Pre-programmed versus Flexible DC Direct Th-cell Development 388
- 20.3.1 Mouse Dendritic Cell Populations in Directing Th-cell Development 388
- 20.3.2 Human Dendritic Cell Populations in Directing Th-cell Development 390
- 20.4 Differential TLR Expression by Distinct Dendritic Cell Populations 392
- 20.4.1 Modulation of TLR Expression 392
- 20.5 Modulation of IL-12p70 or IFN- $\alpha$  Production 393
- 20.6 Factors Responsible for Driving Th2-cell Development 395
- 20.7 Modulation by Tissue Factors 395
- 20.8 Concluding Remarks 396
- References 397

**21 Microbial Instruction of Dendritic Cells 405***Esther C. de Jong, Hermelijn H. Smits, Eddy A. Wierenga and Martien L. Kapsenberg*

- 21.1 Introduction 405
- 21.2 Effector Th1 and Th2 Cells and Regulatory T Cells 405

21.3	Dendritic Cells and Pattern Recognition Receptors	406
21.4	DC-derived Factors that Promote Th1, Th2 or Regulatory T-cell Responses	408
21.4.1	Th1 Cell-promoting Factors	408
21.4.2	Th2 Cell-promoting Factors	410
21.4.3	Regulatory T-cell-promoting Factors	410
21.5	TLR-mediated Activation of DC by Microbes and their Compounds	411
21.5.1	TLR2	411
21.5.2	TLR3	412
21.5.3	TLR4	412
21.5.4	TLR5	413
21.5.5	TLR7/8	413
21.5.6	TLR9	413
21.5.7	TLR10/11	414
21.6	Th1 Cell-promoting DC	414
21.7	Th2 Cell-promoting DC	415
21.8	Regulatory T-cell-promoting DC	415
21.9	Indirect Priming of DC	416
21.10	Concluding Remarks	417
	References	417
<b>VIII</b>	<b>CTL Priming and Crosspresentation</b>	<b>427</b>
<b>22</b>	<b>Crossprocessing and Crosspresentation</b>	<b>427</b>
	<i>Mojca Škoberne and Nina Bhardwaj</i>	
22.1	Introduction	427
22.2	Acquisition of Antigens for Crosspresentation	428
22.2.1	Cells that Crosspresent	428
22.2.2	Sources of Antigens and Receptors involved in Crosspresentation	430
22.2.2.1	Apoptotic Cells	430
22.2.2.2	Necrotic Cells	432
22.2.2.3	Heat-shock Proteins	432
22.2.2.4	Immune Complexes	433
22.2.2.5	Nibbling from Live Cells	434
22.2.2.6	Exosomes	434
22.2.2.7	TLR and MyD88 involvement in Crosspresentation	435
22.3	Mechanisms of Crossprocessing and Crosspresentation	436
22.3.1	Entry into the Classical Endocytic Pathway	436
22.3.2	Phagosome–endosome Compartment	438
22.3.3	A Special Mechanism for Soluble Antigens?	439
22.3.4	Tap Dependence and Endocytic Exchange Mechanism (Vacuolar Pathway)	440
22.3.5	Transfer of Peptides via Gap Junctions	441

22.4	Physiological Relevance of Crosspresentation	442
	Acknowledgements	442
	References	443
<b>23</b>	<b>A Systems Biologist's View of Dendritic Cell–Cytotoxic T Lymphocyte Interaction</b>	<b>455</b>
	<i>Burkhard Ludewig and Gennady Bocharov</i>	
23.1	Introduction	455
23.2	Deciphering the Systems Biologist's Approach	456
23.2.1	Modularity and Protocols	457
23.2.2	Feedback Control	458
23.2.3	Redundancy	460
23.2.4	Structural Stability	461
23.3	From Systems Biology to DC–CTL Immunobiology	461
23.3.1	Dynamics of CTL Activation and Differentiation	462
23.3.2	Multiple Levels of Positive and Negative Feedback Control	463
23.3.2.1	Managing DC Recruitment and Antigen Translocation	464
23.3.2.2	Elimination of DCs by Effector CTL	464
23.3.2.3	Rapid Amplification of Signals through Molecular “Ping–Pong” Interactions	464
23.3.2.4	Limiting the CTL “Overshoot” through Feedforward Control	465
23.3.3	DC Subsets Provide Redundant Activating Signals	466
23.3.4	Tuning of Dendritic Cell Activation	468
23.3.4.1	Excitement through Pattern Recognition	468
23.3.4.2	DC Tuning and Tolerance to Self-antigens	469
23.4	Conclusions	470
	Acknowledgments	470
	References	471
<b>IX</b>	<b>Dendritic Cells Cross-talk with Other Cell Types</b>	<b>481</b>
<b>24</b>	<b>Dendritic Cells and Natural Killer Cells</b>	<b>481</b>
	<i>Magali Terme and Laurence Zitvogel</i>	
24.1	Introduction on NK Cells	481
24.2	Activation of NK Cells by DC	482
24.2.1	NK-cell Activation and DC Subsets	483
24.2.2	Molecular Mechanisms of the DC-mediated NK-cell Activation	483
24.3	Reciprocal Interaction of DC and NK Cells	484
24.3.1	DC Maturation Induced by NK Cells	485
24.3.2	Lysis of DC by Activated NK Cells	485
24.4	Where do DC Meet NK Cells?	486
24.4.1	In Lymph Nodes	486
24.4.2	In the Periphery	487
24.5	DC/NK Cross-talk and T Lymphocytes	487

24.5.1 Bridging Innate and Adaptive Immunity 487  
 24.5.2 Modulation of the DC/NK-cell Cross-talk by CD4<sup>+</sup>CD25<sup>+</sup> Regulatory T Cells and Conventional T Cells 489  
 24.6 The DC/NK-cell Cross-talk in Physiopathology 490  
 24.6.1 In Infectious Diseases 490  
 24.6.1.1 Viral Infections 490  
 24.6.1.2 Bacterial Infections 491  
 24.6.2 In Cancer 491  
 24.7 Concluding Remarks 493  
 References 494

**25 Intercellular Communication via Protein Transfer 499**

*Marca H.M. Wauben*

25.1 What are Exosomes, and Where do they Come From? 499  
 25.2 Which Cells are Targets for Exosomes, and how do Exosomes Interact with these Cells? 500  
 25.3 What is the Consequence of Exosome Binding or Uptake for the Target Cell? 501  
 25.4 What is the Physiological Role of Exosomes in the Immune System? 502  
 25.5 Cell–Cell Contact-dependent Transfer of Membrane Proteins 504  
 25.6 How are Membrane Proteins Transferred Between Immune Cells, and What is their Fate? 506  
 25.7 What is the Physiological Role of Membrane Protein Swapping in the Immune System? 508  
 25.8 Concluding Remarks 509  
 Abbreviations 509  
 References 510

**X Tolerogenic Dendritic Cells 517**

**26 Differentiation Stages and Subsets of Tolerogenic Dendritic Cells 517**

*Manfred B. Lutz*

26.1 Introductory Remarks 517  
 26.2 Mechanisms of T-cell Tolerance Induction 518  
 26.2.1 Ignorance 519  
 26.2.2 Anergy 519  
 26.2.3 Deletion 519  
 26.2.4 Immune Deviation 520  
 26.2.5 The Concept of “Immune Balance” 520  
 26.2.6 Regulation/suppression 521  
 26.2.7 Combinations 521  
 26.3 Tolerogenic DC Subsets *in vivo* 522  
 26.3.1 Thymic DC 522

26.3.2	DC in Lymph Nodes and Spleen	523
26.3.3	Migratory DC from Peripheral Organs	523
26.3.4	Plasmacytoid DC	524
26.4	DC Precursors	524
26.5	Immature DC	525
26.5.1	Tissue Resident DC	525
26.5.2	Induction of T-cell Anergy by Immature DC	525
26.5.3	Maturation Inhibitors	526
26.5.4	Maturation Resistance	526
26.6	Semi-mature DC	528
26.6.1	Steady-state Migratory DC	530
26.7	Fully Mature DC	531
	Acknowledgements	531
	Abbreviations	531
	References	532

## **27 Dendritic Cell Manipulation with Biological and Pharmacological Agents to Induce Regulatory T Cells 545**

*Luciano Adorini and Giuseppe Penna*

27.1	Introduction	545
27.2	Mechanisms Promoting Tolerogenic Dendritic Cells	546
27.2.1	Indoleamine 2,3-dioxygenase	547
27.2.2	Immunoglobulin-like Transcripts	547
27.3	Induction of Tolerogenic Dendritic Cells	548
27.3.1	Biological Agents Promoting Tolerogenic Dendritic Cells	549
27.3.1.1	IL-10	549
27.3.1.2	TGF- $\beta$	550
27.3.1.3	TNF- $\alpha$	550
27.3.1.4	G-CSF	551
27.3.2	Pharmacological Agents Promoting Tolerogenic Dendritic Cells	551
27.4	Induction of Tolerogenic Dendritic Cells by VDR Agonists	553
27.4.1	Tolerogenic Dendritic Cells Induced by VDR Agonists lead to enhancement of regulatory T cells	555
27.4.2	Upregulation of Inhibitory Receptor Expression in Dendritic Cells by VDR agonists	556
27.4.3	Modulation of Chemokine Production by VDR Agonists can affect Recruitment of Effector T cells and CD4 <sup>+</sup> CD25 <sup>+</sup> Ts cells to Inflammatory Sites	557
27.5	Common Features of Agents Leading to Induction of Tolerogenic DCs	558
27.6	Conclusions	559
	References	560

<b>28</b>	<b>Surface Molecules Involved in the Induction of Tolerance by Dendritic Cells</b>	<b>569</b>
	<i>Laura C. Bonifaz</i>	
28.1	Introduction	569
28.2	Dendritic Cells and Central Tolerance	570
28.3	Dendritic Cells and Peripheral Tolerance	570
28.4	C-type Lectin Receptors	571
28.4.1	Advantages of DEC-205 as an Endocytic Receptor for Antigen Presentation	572
28.4.2	DEC-205: an Endocytic Receptor that Preserves the Steady State in the DC after the Capture of the Antigen	573
28.5	Induction of Peripheral Tolerance by Resting Dendritic Cells	573
28.5.1	The Same Dendritic Cells Could Operate in the Induction of Immunity	574
28.5.2	The Induction of Tolerance by Steady-state Dendritic Cells Promotes Avoidance of the Induction of Autoimmunity	574
28.5.3	Surface Molecules are Involved in Peripheral Tolerance Induction by Resting Dendritic Cells through DEC-205	575
28.5.4	Additional Evidence Supports the Role of Resting DC in the Induction of Peripheral Tolerance	575
28.6	Surface Molecules Involved in the Induction of Peripheral Tolerance	576
28.7	Other Receptors Involved in the Induction of Tolerance that can Preserve the Resting of DC or Induce Negative Signaling	577
28.7.1	Integrins	577
28.7.2	Fc Receptors	578
28.7.3	Suppressor and Regulatory T Cells	578
28.8	Notch Ligands as Surface Molecules Involved in the Induction of Regulatory T Cells	579
28.9	ILT-3 and ILT-4: Two Inhibitory Molecules Involved in Tolerance Induction	580
28.10	Special DC for Tolerance?	581
28.11	Regulatory-tolerogenic DC	582
28.12	Concluding Remarks	582
	Acknowledgments	583
	References	583
<b>29</b>	<b>Interaction Between Dendritic Cells and Apoptotic Cells</b>	<b>591</b>
	<i>Adriana T. Larregina and Adrian E. Morelli</i>	
29.1	Introduction	591
29.2	Dendritic Cells Phagocytose and Process Apoptotic Cells	592
29.3	The Phagocytic Synapse	593
29.3.1	Externalized Phosphatidylserine (PS) and Receptors for PS	595
29.3.2	Thrombospondin-1 (TSP-1), CD36 and the Integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$	596



29.3.3	Complement Factors and Complement Receptors (CR)	596
29.3.4	Pentraxins	598
29.3.5	Milk-fat Globule Protein Epidermal Growth Factor 8 (MFG-E8)/lactadherin	598
29.3.6	Other Apoptotic Cell Recognition Signals	599
29.4	Redundant Receptors and Backup Mechanisms for Apoptotic Cell Clearance	600
29.5	Regulatory Effects of Early Apoptotic Cells on Dendritic Cells	600
29.6	Molecular Mechanisms of the Interaction between Dendritic Cells and Apoptotic Cells	602
29.7	Dendritic Cells, Apoptotic Cells and Peripheral Tolerance	603
29.8	The Potential Therapeutical Use of Apoptotic Cells for Peripheral Tolerance	605
29.9	Pathogens and Apoptotic Cell-like Mimicry	607
29.10	Dead Cells and the Delicate Balance between Immunity and Tolerance	608
29.11	Concluding Remarks	610
	Acknowledgements	610
	References	611

### **30 Pharmacologically Modified Dendritic Cells: A Route to Tolerance-associated Genes** 619

*Kathleen F. Nolan, Stephen F. Yates, Alison M. Paterson, Paul J. Fairchild and Herman Waldmann*

30.1	Dendritic Cells, Maturation and Tolerance	619
30.2	Gene Profiling	622
30.2.1	Gene Profiling Technologies	623
30.2.2	Serial Analysis of Gene Expression (SAGE)	624
30.2.2.1	SAGE Methodology	625
30.2.2.2	Handling Raw SAGE Data	627
30.2.3	Accumulation of a Comparative SAGE Resource for Identifying Tolerance-associated Genes	628
30.2.3.1	Relationship of Modulated DC Populations based on Gene Expression Patterns	631
30.2.3.2	Elucidation of “Signatures” of Genes Associated with Tolerance	632
30.2.3.3	Identification of Novel Genes	634
30.2.3.4	AQ4 SAGE Library Comparisons Provide Insights to Biological Mechanism	634
30.3	Downstream Assessment of Tolerance Associated Candidate Genes	636
30.3.1	Simultaneous Assessment of Multiple Candidate Gene Expression Levels using a Custom “ImmunoChip”	636
30.3.2	Assessing the Functional Relevance of Tolerance Candidates by Genetic Manipulation of DCs	637

- 30.3.3 Assessing the Functional Impact of Candidates in an *in vivo* Tolerance Model 638
- 30.4 Downstream Clinical Relevance 638
- References 639

**Part B Dendritic Cells in Disease 649**

**XI Parasites 651**

**31 Malaria 651**

*Britta C. Urban and Francis M. Ndungu*

- 31.1 Introduction to Malaria 651
- 31.2 Antigenic Variation 652
- 31.3 Animal Models for Malaria 653
- 31.4 Acquired Immunity to Malaria 653
  - 31.4.1 Immune Response to Liver Stages 654
  - 31.4.2 Cellular Immunity to the Erythrocytic Stage 654
  - 31.4.3 Humoral Immunity to the Erythrocytic Stage 655
- 31.5 Immune Recognition of iRBC 656
  - 31.5.1 Toll-like Receptors 656
  - 31.5.2 CD36 657
  - 31.5.3 Other Scavenger Receptors 658
  - 31.5.4 Complement and Fc Receptors 658
- 31.6 Dendritic Cells in Malaria 658
  - 31.6.1 DCs in Human Malaria 658
  - 31.6.2 DCs in Rodent Malaria 659
- 31.7 Synopsis 660
- Acknowledgments 662
- References 663

**32 Dendritic Cells in Leishmaniasis: Regulators of Immunity and Tools for New Immune Intervention Strategies 669**

*Heidrun Moll*

- 32.1 Introduction 669
- 32.2 Mechanisms Mediating Resistance or Susceptibility to *Leishmaniasis* 670
  - 32.2.1 The Role of T Helper Cell Subsets 671
  - 32.2.2 The Role of Regulatory T Cells 672
- 32.3 Dendritic Cell Interaction with *Leishmania* Parasites 673
  - 32.3.1 Parasite Uptake by Dendritic Cells 673
  - 32.3.2 Subcellular Location of *Leishmania* Parasites in Dendritic Cells 674
  - 32.3.3 Dendritic Cell Subsets Involved in the Uptake of *Leishmania* 675
  - 32.3.4 Dendritic Cells in *Leishmania*-infected Tissues 676
- 32.4 Dendritic Cell Migration and Induction of a *Leishmania*-specific Immune Response 676

- 32.4.1 The Role of Chemokines and Chemokine Receptors Expressed by Dendritic Cells 677
- 32.4.2 Transport and Presentation of *L. major* Antigen by Dendritic Cells 678
- 32.4.3 Parasite Persistence in Immune Hosts 680
- 32.5 Regulation of the Leishmania-specific Immune Response by Dendritic Cells 680
  - 32.5.1 The Role of IL-12 Production by Dendritic Cells 681
  - 32.5.2 Other Parameters that may Govern the Polarization of T Helper Cells 682
- 32.6 Parasite Evasion of Dendritic Cell Function 683
- 32.7 Dendritic Cells as Tools for Novel Immune Intervention Strategies Against *Leishmaniasis* 685
  - 32.7.1 Dendritic Cell-based Vaccination and Immunotherapy 685
  - 32.7.2 Parameters Determining the Efficacy of Dendritic Cell-based Immune Intervention Strategies 686
- 32.8 Conclusions and Perspectives 687
  - References 688

### 33 Sentinel and Regulatory Functions of Dendritic Cells in the Immune Response to *Toxoplasma gondii* 693

*Alan Sher, Felix Yarovinsky, Romina Goldszmid, Julio Aliberti and Dragana Jankovic*

- 33.1 Introduction 693
- 33.2 Activation of DC by *T. gondii* 694
  - 33.2.1 Responsive DC Subpopulations 694
  - 33.2.2 Host Receptors and Parasite Ligands Involved in Triggering of Murine DC 696
    - 33.2.3 Activation of Human DC 698
  - 33.3 Regulation of DC Activity 699
  - 33.4 Role of DC in *T. gondii*-induced Immune Polarization 700
  - 33.5 Mechanisms of Antigen Presentation to T Cells 702
  - 33.6 Towards an Understanding of DC Function *in vivo* 703
- Acknowledgements 704
- References 705

### 34 *Schistosoma* 709

*Andrew S. MacDonald and Edward J. Pearce*

- 34.1 Introduction 709
- 34.2 DC Response to Schistosome Ag 710
- 34.3 Th2 Induction by DC in Response to Schistosome Ag 714
- 34.4 DC During Schistosome Infection 717
- 34.5 Discussion 718
  - Acknowledgements 719
  - References 719

**XII Bacteria 723****35 Dendritic Cells and Immunity to Salmonella 723***Mary Jo Wick*

- 35.1 Introduction 723
- 35.2 Dendritic Cell Subsets, Short and Sweet 724
- 35.3 Dendritic Cells and Salmonella: Lessons from *in vitro* Studies 724
  - 35.3.1 Bacterial Uptake and the Fate of Internalized Bacteria 724
  - 35.3.2 Presentation of Salmonella Antigens by Dendritic Cells 727
    - 35.3.2.1 Processing of Salmonella for Direct Presentation on MHC-II by Infected Dendritic Cells 727
    - 35.3.2.2 Processing of Salmonella for Direct Presentation on MHC-I by Infected Dendritic Cells 727
    - 35.3.2.3 Modulating of Antigen Presentation by Salmonella 728
    - 35.3.2.4 Waste not, Want not: Dendritic Cells as Bystander Antigen-presenting Cells 729
- 35.4 Time to go to Work: Salmonella-induced Dendritic Cell Maturation 730
- 35.5 Murine Infection Models to Study Dendritic Cell Interaction with Salmonella *in vivo* 733
  - 35.5.1 Salmonella Infection and Penetration of the Intestinal Epithelium 733
  - 35.5.2 Dendritic Cell Take-up Salmonella *in vivo* 734
  - 35.5.3 Getting the Game Started: Dendritic Cells Initiate Adaptive Immunity to Salmonella 734
    - 35.5.3.1 Salmonella-induced Dendritic Cell Maturation During Infection 734
    - 35.5.3.2 Presentation of Salmonella Antigens by Dendritic Cells *in vivo* 736
- 35.6 Concluding Remarks 737
  - Acknowledgements 737
  - References 738

**36 Dendritic Cells in Tuberculosis 745***Ulrich E. Schaible and Florian Winau*

- 36.1 Introduction 745
- 36.2 Tuberculosis 745
- 36.3 Mycobacteria are Intracellular Pathogens 747
- 36.4 Dendritic Cells Present Antigens in Tuberculosis 749
- 36.5 Dendritic Cells are Regulatory Cells in Tuberculosis 752
- 36.6 Dendritic Cells and Cross-Priming 753
- 36.7 Mycobacteria Interfere with Antigen Presenting Cell Function 755
- 36.8 Conclusion 756
  - Acknowledgement 756
  - References 756

- 37 Dendritic Cell–Epithelial Cell Interactions in Response to Intestinal Bacteria 759**  
*Maria Rescigno*
- 37.1 The Intestinal Epithelium and the Gut-associated Lymphoid Tissue (GALT) 759
- 37.2 Antigen Uptake in the Gut and DC Populations 760
- 37.3 Cross-talk between Bacteria and Epithelial Cells 762
- 37.4 Unique Functions of Mucosal DCs 763
- 37.5 Intestinal Immune Homeostasis is Regulated by the Cross-talk between ECs and DCs 764
- 37.6 Cross-talk between ECs and DCs in Bacterial Handling 766
- 37.7 Conclusions 767  
 References 767

### Volume 3

#### XIII Viruses 773

- 38 Sleeping with the Enemy: The Insidious Relationship between Dendritic Cells and Immunodeficiency Viruses 773**  
*L. Vachot, S.G. Turville, S. Trapp, S. Peretti, G. Morrow, I. Frank and M. Pope*
- 38.1 Introduction 773
- 38.1.1 The Global AIDS Epidemic 773
- 38.1.2 Overview of Dendritic Cell Involvement in the Onset and Spread of HIV Infection 774
- 38.1.3 *In vivo* Evidence for DC Involvement in HIV Infection 776
- 38.1.3.1 Macaque Studies on Mucosal DCs and Infection 776
- 38.1.3.2 Changes in DC Biology in Immunodeficiency Virus Infection 777
- 38.2 Consequences of DC–HIV Interplay 778
- 38.2.1 HIV-binding Receptors Expressed by DCs 778
- 38.2.2 HIV Infection of DCs 780
- 38.2.3 Internalization of HIV Particles by DCs 782
- 38.3 DC-to-T-cell Transmission of Infectious Virus 783
- 38.3.1 Immunodeficiency Virus Replication in the DC–T Cell Milieu 783
- 38.3.2 Virus Movement across DC–T-cell Synapses 784
- 38.3.3 Two Phases of Virus Spread from DCs to T Cells 786
- 38.4 Inhibiting DC-driven Infection 788
- 38.4.1 Preventing direct HIV Interactions with DCs and DC–T-Cell Mixtures 788
- 38.4.2 DC-mediated HIV Transmission to T cells 789
- 38.5 Functional Modification of DCs by HIV Favors Infection over Immunity 790
- 38.5.1 Viral Factors Modify moDCs 790

38.5.2	Effects of Virus on Circulating DC Subsets	791
38.5.3	Virus-carrying Immature DCs Activate Substandard Virus-specific T-cell Responses	792
38.6	Implications for Vaccine and Microbicide Strategies	793
38.6.1	Blocking Mucosal Infection	793
38.6.2	Using DCs to Boost Immunity	794
38.6.2.1	DC-induced Primary Responses for Preventative HIV Vaccines	795
38.6.2.2	DC-based Therapeutic Control of Existing Immunodeficiency Virus Infection	796
38.7	Summary and Future Perspectives	797
	Acknowledgements	797
	References	797
<b>39</b>	<b>Cytomegalovirus Infection of Dendritic Cells</b>	<b>813</b>
	<i>Brigitte Sénéchal and James W. Young</i>	
39.1	Introduction	813
39.2	HCMV Induces Immunosuppression	813
39.3	A Role for Dendritic Cells in the Pathology of CMV Infection	814
39.4	The Myeloid Lineage and Monocytes are Major Sites of HCMV Latency	814
39.5	Human Dendritic Cells are a Potential Target for HCMV	815
39.6	<i>In vitro</i> Evidence for HCMV Entry and Replication into Dendritic Cells	816
39.7	HCMV Impairs the Function of Immature Dendritic Cells	817
39.8	HCMV Impairs the Function of Mature Dendritic Cells	818
39.9	Langerhans-type Dendritic Cells are also Permissive to HCMV	819
39.10	Importance of Viral IL-10 in HCMV-induced Immunosuppression	820
39.11	CMV Infection of Dendritic Cells in the Mouse Model	820
39.12	Conclusion	822
	Acknowledgements	823
	References	823
<b>40</b>	<b>Interactions of Hemorrhagic Fever Viruses with Dendritic Cells</b>	<b>829</b>
	<i>Stefan Pöhlmann</i>	
40.1	Introduction	829
40.2	Filoviruses	830
40.2.1	Pathology and Epidemiology	830
40.2.2	Replication	831
40.2.3	Tropism	832
40.2.4	Dendritic Cells are Major Targets of Ebolavirus	832
40.2.5	Filovirus Infection causes Aberrant Dendritic Cell Maturation	833
40.2.6	Filoviral Protein(s) Suppress Dendritic Cell Maturation	834
40.3	Dengue Virus (DEN)	835
40.3.1	Epidemiology and Pathology	835

40.3.2	Replication	836
40.3.3	Dengue Hemorrhagic Fever	836
40.3.4	Skin Dendritic Cells are Early Targets of Dengue Virus	837
40.3.5	Differential Effects of Dengue Virus on Infected and Bystander Dendritic Cells	837
40.4	Lassa Virus (LV)	839
40.5	Hantavirus (HTV)	840
40.6	Filoviruses and DEN Engage DC-SIGN, a Lectin Expressed on DCs	841
40.6.1	DC-SIGN – a Portal for Pathogens	841
40.6.2	Does DC-SIGN Promote Filovirus Infection <i>in vivo</i> ?	842
40.6.3	DC-SIGNR – a DC-SIGN-related Attachment Factor that might Concentrate Filoviruses in Liver and Lymph Nodes	844
40.6.4	Dengue Virus Targets Dendritic Cells via DC-SIGN	844
40.7	Conclusions	845
	Acknowledgements	846
	Abbreviations	846
	References	847

## **41 Dendritic Cells in Measles Virus Pathogenesis 855**

*Marion Abt, Nora Mueller and Sibylle Schneider-Schaulies*

41.1	General Introduction	855
41.2	The Virus: Structure and Genotypes	856
41.3	The Role of Entry Receptors in Measles Virus Pathogenesis	857
41.4	Dendritic Cells in Measles Virus Pathogenesis	859
41.4.1	Measles Virus Interaction with Receptors on Dendritic Cells and Functional Consequences	860
41.4.1.1	Interaction with Surface Receptors	860
41.4.1.2	Functional Consequences of Measles Virus Surface Interaction with Dendritic Cells	861
41.4.2	Impact of Measles Virus on Dendritic Cell Viability and Maturation	862
41.4.3	Impact of Measles Virus on External Maturation/Stimulation Signals in Dendritic Cells	863
41.4.4	Impact of Dendritic Cells Measles Virus Infection on T-cell Viability, Activation and Expansion	864
41.5	Conclusions and Perspectives	865
	Acknowledgment	867
	Abbreviations	868
	References	868

## **42 Dendritic Cells and Herpes Simplex Virus Type 1 875**

*Alexander T. Prechtel and Alexander Steinkasserer*

42.1	The Herpes Simplex Virus Type 1	875
42.1.1	A Well-known Plaque for Centuries	875

- 42.1.2 The Role of Viral Immediate-early Proteins During the Conquest of the Cell 875
- 42.1.3 The Course of Herpes Simplex Virus Type 1 Infection and Replication 878
- 42.2 Herpes Simplex Virus meets Dendritic Cells 879
  - 42.2.1 The Way into Dendritic Cells 879
    - 42.2.1.1 Receptors and Ligands for Cell Entry 879
    - 42.2.1.2 Infection of Different Dendritic Cell Populations by Herpes Simplex Virus Type 1 880
    - 42.2.2 Interference with Typical Functions of Dendritic Cells 881
      - 42.2.2.1 Interference with Dendritic Cell Maturation 881
      - 42.2.2.2 Interference with Dendritic Cell Migration 882
      - 42.2.2.3 Interference with Dendritic-cell-mediated T-cell Stimulation 884
    - 42.3 The Cell Surface Molecule CD83 885
      - 42.3.1 Characteristics of CD83 885
      - 42.3.2 Modulation of Dendritic Cell Function by Interference with CD83 mRNA Processing 886
      - 42.3.3 The Soluble Extracellular Domain of CD83 and its Influence on T-cell Proliferation 887
      - 42.3.4 *The Function of Membrane-bound CD83* 887
      - 42.3.5 Influence of CD83 on the T-cell Development in the Thymus 888
  - Acknowledgements 889
  - Abbreviations 889
  - References 889
- 43 Epstein–Barr Virus 897**
  - Christian Münz*
  - 43.1 The Epstein–Barr Virus (EBV) 897
  - 43.2 Immune Control of Epstein–Barr Virus 898
  - 43.3 Stimulation of Lymphocyte Compartments Relevant to Epstein–Barr Virus Immune Control *in vitro* 899
    - 43.3.1 Tonsillar Natural Killer Cell Activation by Dendritic Cells and its Possible Role in Epstein–Barr Virus Infection 899
    - 43.3.2 Initiation of Epstein–Barr Virus-specific T-cell Immunity by Dendritic Cells 900
  - 43.4 Evidence for Priming of Epstein–Barr Virus Immune Control by Dendritic Cells *in vivo* 901
    - 43.4.1 Strong Th1 Polarization of CD4<sup>+</sup> T-cell Responses to the Nuclear Antigen 1 of Epstein–Barr Virus (EBNA1) 901
    - 43.4.2 Priming of Epstein–Barr Virus-specific Responses by Crosspresentation via Dendritic Cells Leads to Heterogeneous Affinity of T-cell Responses 903
  - 43.5 Detection of Epstein–Barr Virus Infection by the Immune System 903



43.6	Immunotherapeutic use of Dendritic Cells against Epstein–Barr Virus	904
43.7	Summary	905
	References	906
<b>XIV</b>	<b>Fungi</b>	<b>915</b>
<b>44</b>	<b>Dendritic Cells in Immunity and Vaccination against Fungi</b>	<b>915</b>
	<i>Luigina Romani and Paolo Puccetti</i>	
44.1	Introduction	915
44.2	Immunity to Fungi	916
44.3	Dendritic Cells at the Host/Fungi Interface	917
44.3.1	Fungal Recognition by Dendritic Cells and Receptor Cooperativity	918
44.3.2	Dendritic Cell Activation	921
44.3.3	Dendritic Cell Conditioning	923
44.3.3.1	Opsonins	923
44.3.3.2	Tryptophan Metabolic Pathway	924
44.3.3.3	T-cell Ligands	925
44.3.3.4	Other Cells	925
44.4	Dendritic Cells Translate Fungus-associated Information to Th1, Th2 and Treg Cells	926
44.5	Exploiting Dendritic Cells as Fungal Vaccines	927
44.6	Conclusions and Perspectives	928
	Acknowledgements	929
	Abbreviations	929
	References	930
<b>XV</b>	<b>Autoimmunity</b>	<b>935</b>
<b>45</b>	<b>Dendritic Cells in Autoimmune Diseases</b>	<b>935</b>
	<i>Alexis Mathian, Sophie Koutouzov, Virginia Pascual, A. Karolina Palucka and Jacques Banchereau</i>	
45.1	Introduction	935
45.2	Dendritic Cells	936
45.3	Dendritic Cells and Tolerance	936
45.3.1	Central Tolerance	936
45.3.2	Dendritic Cells and the Control of Peripheral Tolerance	938
45.4	Dendritic Cell Activation and the Priming of Autoimmune Diseases	939
45.4.1	Autoimmunity through Bystander Activation of Dendritic Cells	940
45.4.1.1	Systemic Lupus Erythematosus as an IFN- $\alpha$ Driven Disease	941
45.4.2	Defective Downregulation of Activated Dendritic Cells	942
45.4.3	The Rise of “Autoimmune-prone” Dendritic Cell Subsets	942

- 45.5 Dendritic Cells Migrate into Inflammatory Sites and Maintain a Vicious Circle 945
- 45.6 Dendritic Cells: Failure to Maintain Peripheral Tolerance 946
- 45.7 A Special Role for Plasmacytoid Dendritic Cells in Systemic *Lupus Erythematosus* 947
  - 45.7.1 Plasmacytoid Dendritic Cells as the Main Producer of Type I IFN in Systemic *Lupus Erythematosus* 948
  - 45.7.2 Plasmacytoid Dendritic Cells Induce Plasma Cell Differentiation 948
- 45.8 Dendritic Cells Fail to Delete Developing Autoreactive T Cells 949
- 45.9 Autoimmunity Through Cytokine-induced Dendritic Cell Activation 949
- 45.10 Different Cytokines Generate Different Dendritic Cells that may lead to Different Autoimmune Syndromes 950
- 45.11 Concluding Remarks 951
  - Acknowledgements 951
  - References 952

**XVI Transplantation 967**

**46 Role of Dendritic Cells in Graft Rejection and Graft-versus-host Disease 967**

*Véronique Flamand and Michel Goldman*

- 46.1 Alloantigen Presentation in Organ Transplantation 967
  - 46.1.1 Pathways of Alloantigen Recognition 967
    - 46.1.1.1 The Direct and Indirect Pathways 967
    - 46.1.1.2 The Semi-direct Pathway 969
  - 46.1.2 Sites of Alloantigen Presentation 970
  - 46.1.3 Factors Inducing Dendritic Cell Maturation and Migration 971
    - 46.1.3.1 Ischemia/reperfusion Injury 971
    - 46.1.3.2 Links between Innate and Adaptive Immunity during Allograft Rejection 972
- 46.2 Alloantigen Presentation during Graft-versus-host Disease 973
  - 46.2.1 Dual Impact of Alloreactive T Cells during Graft-versus-host Disease 973
    - 46.2.2 Role of Host Dendritic Cells 974
      - 46.2.2.1 Host Dendritic Cells in the Initiation and Effector Phases of Graft-versus-host Disease 974
      - 46.2.2.2 Attempts to Eliminate Host Dendritic Cells 975
      - 46.2.2.3 The Effects of Recipient Conditioning on Dendritic Cell Maturation 975
      - 46.2.2.4 Reconstitution of Dendritic Cell Content LAQ1L 976
    - 46.2.3 Role of Donor Dendritic Cells 977
  - Acknowledgements 977
  - References 978

<b>47</b>	<b>Dendritic Cells and Transplantation Tolerance</b>	<b>983</b>
	Paul J. Fairchild, Stephen F. Yates and Herman Waldmann	983
47.1	The Expanding World of Transplantation	983
47.2	The Role of Dendritic Cells in Allograft Rejection	985
47.2.1	Direct Presentation of Alloantigen	985
47.2.2	Indirect Presentation of Alloantigen	986
47.2.3	The Semi-direct Pathway of Alloantigen Presentation	987
47.2.4	Pathways of Antigen Presentation during Cell Replacement Therapy	988
47.3	The Role of Dendritic Cells in Self-tolerance	989
47.3.1	A Cell Type with Two Persona	989
47.3.2	Dendritic Cell Subsets Devoted to Tolerance	990
47.3.2.1	Dendritic Cells Expressing CD8 $\alpha$	990
47.3.2.2	Plasmacytoid Dendritic Cells	991
47.3.2.3	“Regulatory” Dendritic Cells	993
47.3.3	The Maturation Status of Dendritic Cells	994
47.3.3.1	Immature Dendritic Cells have an Enhanced Capacity to be Tolerogenic	994
47.3.3.2	Maturation of Dendritic Cells as a Trigger Point for Immunity	996
47.4	Exploitation of Dendritic Cells for Transplantation Tolerance	997
47.4.1	Central Deletion of Alloreactive T Cells	997
47.4.2	Peripheral Regulation of Alloreactive T Cells	1000
47.4.3	Reinforcing a Tolerogenic Phenotype by Genetic Modification	1001
47.5	Prospects for the Induction of Tolerance via the Indirect Pathway	1002
47.6	Immune Intervention in Cell Replacement Therapy	1005
47.6.1	Generation of Hematopoietic Stem Cells (HSC) for Mixed Chimerism	1005
47.6.2	Generation of Dendritic Cells for Tolerance Induction	1006
	References	1008
<b>48</b>	<b>Dendritic Cells, Immune Regulation and Transplant Tolerance</b>	<b>1017</b>
	<i>Giorgio Raimondi and Angus W. Thomson</i>	
48.1	Introduction	1017
48.2	Dendritic Cells and Initiation of the Rejection Response	1017
48.3	Direct versus Indirect Pathways of Alloreognition	1020
48.4	Dendritic Cells and Tolerance Induction	1021
48.5	Mechanisms underlying Dendritic-cell-induced T-cell Tolerance	1022
48.6	Dendritic Cells and the Control of Organ Transplant Outcome	1026
48.6.1	Dendritic Cell Manipulation for Tolerance Induction: Specific Culture Conditions	1027
48.6.2	Dendritic Cell Manipulation for Tolerance Induction: Pharmacological Manipulation	1027
48.6.3	Dendritic Cell Manipulation for Tolerance Induction: Genetic Engineering	1028

48.6.4	Use of Specific Dendritic Cell Subsets for Tolerance Induction	1029
48.6.5	Dendritic Cell Therapy: Targeting the Indirect Pathway	1031
48.6.6	Dendritic Cells and the Treatment of Chronic Rejection	1033
48.7	Dendritic Cells and Cellular Markers of Transplant Tolerance	1034
48.8	Toward Clinical Use of Dendritic-cell-based Therapies for Tolerance Induction: Critical Considerations and Future Challenges	1035
48.8.1	Dendritic Cell–T Cell Interaction	1035
48.8.2	Dendritic Cells and Treg: a Complex Inter-relationship	1036
48.8.3	Fingerprints of “Tolerogenic” Dendritic Cells	1037
48.8.4	Dendritic Cells at the Crossroads of the Immune System	1037
48.9	Conclusions	1038
	Acknowledgments	1038
	References	1039
<b>XVII</b>	<b>Allergy, Asthma</b>	<b>1047</b>
<b>49</b>	<b>Nickel Presentation to T Cells in Contact Hypersensitivity</b>	<b>1047</b>
	<i>H. U. Weltzien, K. Gernerding and H.-J. Thierse</i>	
49.1	Introduction	1047
49.2	Molecular Basis of Nickel Presentation to Human T Cells	1048
49.2.1	CD4-positive T Cells	1048
49.2.2	CD8-positive T Cells and Non-HLA Restricted Nickel Presentation	1051
49.3	Nickel-Binding Proteins	1051
49.3.1	A Role for Carrier Proteins in Nickel Presentation	1051
49.3.2	Heatshock Proteins as Nickel Binders	1052
49.4	Concluding Remarks	1053
	References	1055
<b>50</b>	<b>Dendritic Cells in Asthma</b>	<b>1059</b>
	<i>Hamida Hammad and Bart N. Lambrecht</i>	
50.1	Introduction	1059
50.2	Asthma as a Th2 Driven Disorder	1059
50.3	Lung Dendritic Cell Subsets	1061
50.4	Function of Lung Dendritic Cells in Primary Immune Responses to Inhaled Antigen and Sensitization to Inhaled Allergen	1062
50.5	Is Tolerance Induction in the Lung a Property of Specialized Dendritic Cell Subsets?	1065
50.6	Accumulation of Mature Dendritic Cells in Ongoing Asthmatic Inflammation	1066
50.7	Direct Proof for a Functional Role for Dendritic Cells in Stimulating Effector Th2 Responses	1068
50.8	Determinants of Dendritic Cell Driven Th2 Responses in Asthma	1069
50.9	Dendritic Cells in Human Asthma	1071
50.10	Conclusion	1072
	References	1073

**XVIII Cancer 1081****51 Dendritic Cells in Human Cancer 1081***Casey A. Carlos and Olivera J. Finn*

51.1 Introduction 1081

51.2 Dendritic Cell Functions that are Important for Effective Immunity against Cancer 1082

51.3 Dendritic Cell Recognition of Malignant Changes in Tissues 1083

51.4 How Tumors Interfere with Normal Dendritic Cell Function 1084

51.4.1 Inhibition of Maturation and Differentiation 1084

51.4.2 Influence on Migration 1085

51.4.3 Suppression of Function 1086

51.5 Summary 1087

References 1088

**Part C Therapeutical Applications of Dendritic Cells 1093****XIX Cancer 1095****52 Dendritic Cell Subsets as Targets and Vectors for Vaccination 1095***Hideki Ueno, Joseph Fay, Jacques Banchereau and A. Karolina Palucka*

52.1 Introduction 1095

52.2 Cancer Vaccines 1096

52.3 Dendritic Cells 1097

52.3.1 Dendritic Cell Subsets 1097

52.3.2 Distinct Dendritic Cell Subsets Induce Distinct Types of Immune Response 1099

52.3.3 Dendritic Cells and Immune Tolerance 1100

52.4 Dendritic Cells as Cancer Vaccines 1100

52.4.1 Dendritic Cell Subsets 1100

52.4.2 Dendritic Cell Maturation 1101

52.4.3 Dendritic Cell Migration 1102

52.4.4 Antigen Loading 1103

52.5 Regulatory/suppressor Mechanisms 1104

52.6 Immunological and Clinical Efficacy 1105

52.6.1 Immunological Efficacy 1105

52.6.2 Clinical Efficacy 1106

52.7 Conclusions 1107

Acknowledgements 1107

References 1107

<b>53</b>	<b>Renal Cell Carcinoma</b>	<b>1117</b>
	<i>Martin Thurnher, Thomas Putz, Andrea Rahm, Hubert Gander, Reinhold Ramoner, Georg Bartsch, Lorenz Höfler and Claudia Falkensammer</i>	
53.1	Dendritic Cells and Cancer Immunosurveillance	1117
53.2	Renal Cell Carcinoma	1117
53.3	Immunotherapy of Renal Cell Carcinoma	1118
53.4	Dendritic Cell-based Immunotherapy of Renal Cell Carcinoma	1119
53.4.1	The Two-step Culture System	1119
53.4.2	Generation of Clinical Grade Dendritic Cells	1119
53.4.3	Clinical Trials of Dendritic Cells in Renal Cell Carcinoma Patients	1120
53.5	Adjuvant Immunotherapy of Organ Confined Renal Cell Carcinoma after Partial or Radical Nephrectomy	1122
53.6	Patient Selection in Future Trials	1123
53.7	Adverse Effects – Quality of Life	1123
53.8	Concluding Remarks	1124
	Acknowledgements	1124
	References	1124
<b>XX</b>	<b>Antigen Delivery</b>	<b>1129</b>
<b>54</b>	<b>Crosspresentation and Loading of Tumor Antigens for Dendritic Cell Vaccination against Cancer</b>	<b>1129</b>
	<i>Madhav V. Dhodapkar</i>	
54.1	Approaches to Antigen Loading for Dendritic-cell-mediated Immunotherapy	1129
54.2	Importance of Receptor-mediated Uptake to Crosspresentation	1130
54.3	Uptake of Dying Cells	1131
54.4	Uptake of Immune Complexes and Opsonized Pathogens and Tumor Cells	1131
54.5	Uptake of Heat Shock Protein–Peptide Complexes	1132
54.6	Exosomes as Sources of Multiple Tumor Antigens	1133
54.7	Role of C-type Lectin Receptors	1133
54.8	Other Routes of Antigen Entry for Crosspresentation	1133
54.9	Processing of the Antigenic Cargo	1134
54.10	Nature of the Antigenic Cargo	1134
54.11	Regulation of Crosspresentation during Dendritic Cell Maturation	1135
54.12	Role of Dendritic Cell Subsets in Crosspresentation	1136
54.13	Some Approaches to Improve Antigen Loading of Dendritic Cells for Clinical Vaccination	1136
54.14	Concluding Remarks	1137
	References	1138

<b>55</b>	<b>Nucleic Acid Transfer</b>	<b>1143</b>
	<i>Niels Schaft, Jan Dörrie and Dirk M. Nettelbeck</i>	
55.1	General Introduction	1143
55.2	Antigen Delivery to DC by Adenoviral Gene Transfer	1145
55.2.1	Recombinant Adenovirus as Gene Transfer Vector	1146
55.2.2	Adenoviral Gene Transfer into Dendritic Cells in Vitro	1149
55.2.3	Adenoviral Antigen Delivery to DC for Ex Vivo Tumor Vaccination in Mouse Tumor Models	1151
55.2.4	Adenoviral Ag Delivery for HIV/SIV Vaccination in Monkeys	1153
55.3	Antigen Delivery to DC by Transfection of Nucleic Acids	1154
55.3.1	Passive Pulsing	1155
55.3.2	Electroporation	1156
55.3.3	Lipofection	1159
55.4	Concluding Remarks	1160
	References	1161
	<b>Subject Index</b>	<b>1173</b>